RCS - PureTech Health PLC - PRTC Appoints Peel Hunt Joint UK Corporate Broker

Puretech HealthAnnouncement

09/04/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250409:nRSI2139Ea&default-theme=true

RNS Number : 2139E  PureTech Health PLC  09 April 2025

9 April 2025

 

PureTech Health plc

 

PureTech Appoints Peel Hunt as Joint UK Corporate Broker

 

PureTech Health plc (https://puretechhealth.com/) (Nasdaq: PRTC, LSE: PRTC)
("PureTech" or the "Company"), is pleased to announce that it has appointed
Peel Hunt as Joint UK Corporate Broker alongside UBS.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving
life to new classes of medicine to change the lives of patients with
devastating diseases. The Company has created a broad and deep pipeline
through its experienced research and development team and its extensive
network of scientists, clinicians and industry leaders that is being advanced
both internally and through its Founded Entities. PureTech's R&D
engine has resulted in the development of 29 therapeutics and therapeutic
candidates, including three that have been approved by the U.S. Food and
Drug Administration. A number of these programs are being advanced
by PureTech or its Founded Entities in various indications and stages of
clinical development, including registration-enabling studies. All of the
underlying programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and then
advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com/)  or connect with us on X (formerly Twitter)
@puretechh.

 

Contact:

PureTech

Public Relations

publicrelations@puretechhealth.com (mailto:publicrelations@puretechhealth.com)

Investor Relations

IR@puretechhealth.com (mailto:IR@puretechhealth.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUPUWWCUPAPGR